1. Home
  2. GBIO vs ATLO Comparison

GBIO vs ATLO Comparison

Compare GBIO & ATLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • ATLO
  • Stock Information
  • Founded
  • GBIO 2016
  • ATLO 1903
  • Country
  • GBIO United States
  • ATLO United States
  • Employees
  • GBIO N/A
  • ATLO N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • ATLO Major Banks
  • Sector
  • GBIO Health Care
  • ATLO Finance
  • Exchange
  • GBIO Nasdaq
  • ATLO Nasdaq
  • Market Cap
  • GBIO 29.5M
  • ATLO 177.0M
  • IPO Year
  • GBIO 2020
  • ATLO N/A
  • Fundamental
  • Price
  • GBIO $5.77
  • ATLO $20.42
  • Analyst Decision
  • GBIO Buy
  • ATLO
  • Analyst Count
  • GBIO 4
  • ATLO 0
  • Target Price
  • GBIO $10.67
  • ATLO N/A
  • AVG Volume (30 Days)
  • GBIO 76.7K
  • ATLO 12.7K
  • Earning Date
  • GBIO 11-05-2025
  • ATLO 11-07-2025
  • Dividend Yield
  • GBIO N/A
  • ATLO 3.89%
  • EPS Growth
  • GBIO N/A
  • ATLO 43.95
  • EPS
  • GBIO N/A
  • ATLO 1.53
  • Revenue
  • GBIO $21,230,000.00
  • ATLO $57,731,000.00
  • Revenue This Year
  • GBIO N/A
  • ATLO N/A
  • Revenue Next Year
  • GBIO N/A
  • ATLO N/A
  • P/E Ratio
  • GBIO N/A
  • ATLO $13.36
  • Revenue Growth
  • GBIO 61.15
  • ATLO 12.59
  • 52 Week Low
  • GBIO $3.00
  • ATLO $15.69
  • 52 Week High
  • GBIO $29.10
  • ATLO $20.75
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 50.66
  • ATLO 63.31
  • Support Level
  • GBIO $5.51
  • ATLO $20.26
  • Resistance Level
  • GBIO $6.04
  • ATLO $20.72
  • Average True Range (ATR)
  • GBIO 0.32
  • ATLO 0.35
  • MACD
  • GBIO -0.10
  • ATLO -0.00
  • Stochastic Oscillator
  • GBIO 26.80
  • ATLO 71.30

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About ATLO Ames National Corporation

Ames National Corporation is a United States-based bank holding company. It provides short-term and medium-term commercial, multi-family, and agricultural real estate loans, residential real estate loans, agricultural and business operating loans and lines of credit, equipment loans, vehicle loans, personal loans and lines of credit, home improvement loans and origination of mortgage loans for sale into the secondary market. The Banks also offer a variety of checking, savings and time deposits, cash management services, merchant credit card processing, safe deposit boxes, wire transfers, direct deposit and automated/video teller machine access. The banking segment generates revenues through personal, business, agricultural and commercial lending, and Others.

Share on Social Networks: